Threshold Pharmaceuticals Inc - Current report filing (8-K)
September 02 2008 - 1:44PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: August 29, 2008
(Date of Earliest Event Reported)
THRESHOLD PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
001-32979
|
|
94-3409596
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
1300 Seaport Boulevard
Redwood City, California 94063
(Address of Principal Executive Offices)(Zip
Code)
(650) 474-8200
(Registrants Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 3.02
|
Unregistered Sales of Equity Securities
|
On
August 29, 2008, Threshold Pharmaceuticals, Inc. (the Company) sold to certain investors (the Offering) an aggregate of 8,970,574 shares of its common stock for a purchase price equal to $2.04 per share and warrants
exercisable for a total of 3,588,221 shares of its common stock with an exercise price equal to $2.34 per share (subject to adjustment). The Company received aggregate gross proceeds equal to approximately $18.3 million in connection with the
Offering. Net proceeds generated from the Offering were approximately $17.0 million. The warrants expire on August 29, 2013. The Offering was consummated pursuant to the terms and conditions of that certain securities purchase agreement (the
Purchase Agreement) entered into by the Company on July 9, 2008, with the investors named therein. A special meeting of the Companys stockholders was held on Friday, August 22, 2008, at which the Companys
stockholders approved the sale and issuance of the shares of common stock and warrants in connection with the Offering. The number of shares of common stock issued and exercisable under the warrants as well as the purchase price of the common stock
and the exercise price of the warrants described in this paragraph give effect to the reverse stock split effected by the Company as of August 20, 2008.
The Offering is exempt from registration pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(2) the Securities Act of 1933, as amended (the Act),
and Regulation D under the Act.
The shares and warrants sold in the Offering and the shares issuable upon the exercise of the related
warrants have not been registered under the Act or any state securities laws, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from SEC
registration requirements. The shares and warrants were offered and sold only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares issued in the private placement and the
shares issuable upon the exercise of the warrants.
On September 2, 2008, the Company issued the
press release attached hereto as Exhibit 99.1 regarding the transaction described in this report.
Item 9.01
|
Financial Statements and Exhibits
|
99.1
|
Press Release dated September 2, 2008
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
THRESHOLD PHARMACEUTICALS, INC.
|
|
|
By:
|
|
/s/ J
OEL
A. F
ERNANDES
|
|
|
Joel A. Fernandes
Senior Director, Finance and
Controller
|
Date: September 2, 2008
Threshold Pharmaceuticals (MM) (NASDAQ:THLDD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Threshold Pharmaceuticals (MM) (NASDAQ:THLDD)
Historical Stock Chart
From Jul 2023 to Jul 2024